Visceral Leishmaniasis in Latin America and Therapy perspectives

Leishmaniasis visceral en América Latina y perspectivas terapéuticas

In Latin America, visceral leishmaniasis is caused by Leishmania infantum. In this geographical area, main vectors associated with transmission are Lutzomyia longipalpis and Lutzomyia evansi, with dogs being incriminated as the main reservoir involved in transmission of the disease. This pathology primarily affects children between 0 - 5 years, a highly susceptible population where socio-economic, environmental and nutritional factors affects the pathological outcome and increase the likelihood of vector-human contact. According to the World Health Organization (WHO) recommended treatment for Visceral Leishmaniasis is liposomal amphotericin B, a drug with a limited and variable availability between countries depending on market prices, which leaves pentavalent antimonial as the most widely used treatment despite the associated toxic effects. In the Americas, evidence on the efficacy of single-dose (monotherapy) and combination therapies as options for treating these parasites is required.

1. Fernández MJ, Charry CT, Bello GF, Escovar J, Lozano C, Ayala S M, et al. Prevalence of canine visceral leishmaniasis in municipalities of Huila, Colombia. Rev Salud Pública 2016; 4(3):278–85.
3. Ready P. Epidemiology of visceral leishmaniasis. Clin Epidemiol 2014; 6:147. https://doi.org/10.2147/CLEP.S44267
5. Cruz-Hernández V, León-Tapia S, Cruz-Reyes MÁ, Sosa-López R, Arango-Díaz Á, González-Sánchez E. Leishmaniasis visceral, reporte de cuatro casos y revisión de la bibliografía. Med Interna México 2013; 29(2):204–9.
7. Herwaldt BL. Leishmaniasis. Lancet 1999; 354(9185):1191–9. https://doi.org/10.1016/S0140-6736(98)10178-2
9. OMS | Leishmaniasis [Internet]. Nota descriptiva No. 375 Febrero de 2015. World Health Organization; 2015 [cited 2016 May 11]. Available from: http://www.who.int/mediacentre/factsheets/fs375/es/
11. Lara-Silva F de O, Michalsky ÉM, Fortes-Dias CL, Fiuza V de OP, Pessanha JEM, Regina-Silva S, et al. Epidemiological aspects of vector, parasite, and domestic reservoir in areas of recent transmission and no reported human cases of visceral leishmaniasis in Brazil. Acta Trop 2015; 148:128–36. https://doi.org/10.1016/j.actatropica.2015.04.002
13. Pan American Health Organization. LEISHMANIASES Epidemiological Report of the Americas. Report Leishmaniases No 2 - June, 2014 [Internet]. 2014. Available from: http://new.paho.org/leishmaniasis
15. Organización Panamericana de la Salud; Organización Mundial de la Salud. Leishmaniasis: Informe Epidemiológico de las Américas [Internet]. 2015 [cited 2016 May 13]. Available from: http://www.paho.org/hq/index.php?option=com_topics&view=article&id=29&Itemid=40754&lang=es
17. Albuquerque LCP de, Mendonça IR, Cardoso PN, Baldaçara LR, Borges MRMM, Borges J da C, et al. HIV/AIDS-related visceral leishmaniasis: a clinical and epidemiological description of visceral leishmaniasis in northern Brazil. Rev Soc Bras Med Trop 2016; 47(1):38–46. https://doi.org/10.1590/0037-8682-0180-2013
19. Lindoso JA, Cota GF, da Cruz AM, Goto H, Maia-Elkhoury ANS, Romero GAS, et al. Visceral leishmaniasis and HIV coinfection in Latin America. PLoS Negl Trop Dis 2014; 8(9):e3136. https://doi.org/10.1371/journal.pntd.0003136
21. Roselino AM, Chociay MF, Costa RS, Machado AA, Figueiredo JF de C. L. (L.) chagasi in AIDS and visceral leishmaniasis (kala-azar) co-infection. Rev do Inst Med Trop São Paulo 2008; 50(4):251–4. https://doi.org/10.1590/S0036-46652008000400012
23. Jarvis JN, Lockwood DN. Clinical aspects of visceral leishmaniasis in HIV infection. Curr Opin Infect Dis 2013; 26(1):1–9. https://doi.org/10.1097/QCO.0b013e32835c2198
25. Cota GF, de Sousa MR, Demarqui FN, Rabello A. The diagnostic accuracy of serologic and molecular methods for detecting visceral leishmaniasis in HIV infected patients: meta-analysis. PLoS Negl Trop Dis 2012; 6(5):e1665. https://doi.org/10.1371/journal.pntd.0001665
27. Pintado V, López-Vélez R. Leishmaniasis visceral asociada a la infección por el virus de la inmunodeficiencia humana. Enferm Infecc Microbiol Clin 2001; 19(7):353–7. https://doi.org/10.1016/S0213-005X(01)72665-1
29. Ministerio de la protección Social; Instituto Nacional de Salud; Organización Panamericana de la Salud. Guía para la Atención Clínica Integral del paciente con Leishmaniaiss [Internet]. Bogotá; 2010 [cited 2016 May 13]. Available from: http://www.ins.gov.co/temas-de-interes/leishmaniasis viceral/02 clinica leishmaniasis.pdf
31. Instituto Nacional de Salud. Boletín Epidemiológico No. 52 de 2015 [Internet]. Bogotá; 2015 [cited 2016 May 13]. Available from: http://www.ins.gov.co/boletin-epidemiologico/Boletn Epidemiolgico/2015 Boletin epidemiologico Semana 52.pdf
33. Cantillo-Barraza O, Gómez-Palacio A, Salazar D, Mejía-Jaramillo AM, Calle J, Triana O. Distribución geográfica y ecoepidemiología de la fauna de triatominos (Reduviidae: Triatominae) en la Isla Margarita del departamento de Bolívar, Colombia. Biomédica. 2010; 30(3):382–9. https://doi.org/10.7705/biomedica.v30i3.272
35. Hernández CPZ, Sotelo MSA, Oviedo OPF, Barraza OC, Toro GR. Cartagena: nuevo foco de leishmaniasis visceral urbana en Colombia [Internet]. CIENCIA EN DESARROLLO. 2016; 7(1):83–91. Available from: http://revistas.uptc.edu.co/revistas/index.php/ciencia_en_desarrollo/article/view/4234
37. Zambrano Hernandez C del P, Ayala Sotelo MS, Fuya Oviedo OP, Montenegro Puentes CA, Aya Vanegas NM, Rodriguez Toro JG, et al. Brote urbano de leishmaniasis visceral en Neiva (Huila), 2012. Rev Salud Pública 2015; 17(4):514–27. https://doi.org/10.15446/rsap.v17n4.44663
39. Vélez ID, Travi BL, Gallego J, Palma GI, Agudelo S del P, Montoya J, et al. Evaluación ecoepidemiológica de la leishmaniosis visceral en la comunidad indígena Zenú de San Andrés de Sotavento, Córdoba: primer paso para su control. Rev Colomb Entomol. 1995;21(3):111–22.
41. Vivero RJ, Torres-Gutierrez C, Bejarano EE, Pe-a HC, Estrada LG, Florez F, et al. Study on natural breeding sites of sand flies (Diptera: Phlebotominae) in areas of Leishmania transmission in Colombia. Parasit Vectors 2015; 8(1):116. https://doi.org/10.1186/s13071-015-0711-y
43. Teixeira C, Gomes R, Collin N, Reynoso D, Jochim R, Oliveira F, et al. Discovery of markers of exposure specific to bites of Lutzomyia longipalpis, the vector of Leishmania infantum chagasi in Latin America. PLoS Negl Trop Dis 2010; 4(3):e638. https://doi.org/10.1371/journal.pntd.0000638
45. Vivero RJ, Bejarano EE, Pérez-Doria A, Flórez F, Estrada LG, Torres C, et al. Nuevos registros de flebotomíneos (Diptera: Psychodidae), con el hallazgode Lutzomyia longipalpis (Lutz & Neiva, 1912), en los alrededoresde la Ciudad de Sincelejo, Colombia. Biota Neotrop, 2009; 9(4):277–80. https://doi.org/10.1590/S1676-06032009000400031
47. Cortés Alemán L, Pérez-Doria A, Bejarano Martínez EE. Flebotomíneos (Diptera: Psychodidae) antropofílicos de importancia en salud pública en Los Montes de María, Colombia. Rev Cubana Med Trop 2009; 61(3):220–5.
49. Paternina LE, Verbel-Vergara D, Romero-Ricardo L, Pérez-Doria A, Paternina-Gómez M, Martínez L, et al. Evidence for anthropophily in five species of phlebotomine sand flies (Diptera: Psychodidae) from northern Colombia, revealed by molecular identification of bloodmeals. Acta Trop 2016; 153:86–92. https://doi.org/10.1016/j.actatropica.2015.10.005
51. M. JIG, Vélez ID. Presencia en Isla Fuerte, Bolívar de Lutzomyia evansi vector de leishmaniosis visceral. Iatreia. 1994; 7(1):33–5.
53. Barreto M, Burbano ME, Barreto P. Registros de Lutzomyia (Diptera: Psychodidae) en nuevas localidades de Colombia. Colombia Médica. 2006; 37(1):39–45.
55. González C, Paz A, Ferro C. Predicted altitudinal shifts and reduced spatial distribution of Leishmania infantum vector species under climate change scenarios in Colombia. Acta Trop 2014; 129:83–90. https://doi.org/10.1016/j.actatropica.2013.08.014
57. Romero M, López M, Echeverry M, Rivas F. Canine Visceral Leishmaniasis: Diagnostic tests do not detect real state of the infection. Rev Salud Pública 2008; 10(2):290–8. https://doi.org/10.1590/S0124-00642008000200009
59. Paternina-Gómez M, Díaz-Olmos Y, Paternina LE, Bejarano EE. Alta prevalencia de infección por Leishmania (Kinetoplastidae: Trypanosomatidae) en caninos del norte de Colombia. Biomédica 2013; 33(3):375–82. https://doi.org/10.7705/biomedica.v33i3.780
61. Roque ALR, Jansen AM. Wild and synanthropic reservoirs of Leishmania species in the Americas. Int J Parasitol Parasites Wildl 2014; 3(3):251–62. https://doi.org/10.1016/j.ijppaw.2014.08.004
63. Travi BL, Jaramillo C, Montoya J, Segura I, Zea A, Goncalves A, et al. Didelphis marsupialis, an important reservoir of Trypanosoma (Schizotrypanum) cruzi and Leishmania (Leishmania) chagasi in Colombia. Am J Trop Med Hyg 1994; 50(5):557–65. https://doi.org/10.4269/ajtmh.1994.50.557
65. Travi B. Leishmaniasis visceral canina. Rev MVZ CORDOBA. 2000; 5(1):29–32.
67. Hatam GR, Adnani SJ, Asgari Q, Fallah E, Motazedian MH, Sadjjadi SM, et al. First report of natural infection in cats with Leishmania infantum in Iran. Vector Borne Zoonotic Dis 2010; 10(3):313–6. https://doi.org/10.1089/vbz.2009.0023
69. da Silva SM, Rabelo PFB, Gontijo N de F, Ribeiro RR, Melo MN, Ribeiro VM, et al. First report of infection of Lutzomyia longipalpis by Leishmania (Leishmania) infantum from a naturally infected cat of Brazil. Vet Parasitol 2010; 174(1–2):150–4. https://doi.org/10.1016/j.vetpar.2010.08.005
71. Alam MS, Ghosh D, Khan MGM, Islam MF, Mondal D, Itoh M, et al. Survey of domestic cattle for anti-Leishmania antibodies and Leishmania DNA in a visceral leishmaniasis endemic area of Bangladesh. BMC Vet Res 2011; 7(1):27. https://doi.org/10.1186/1746-6148-7-27
73. Quinnell RJ, Courtenay O. Transmission, reservoir hosts and control of zoonotic visceral leishmaniasis. Parasitology 2009; 136(14):1915–34. https://doi.org/10.1017/S0031182009991156
75. Organización Panamericana de la Salud. Leishmaniasis visceral en las Américas Recomendaciones para el Tratamiento [Internet]. Washington, DC; 2013. Available from: http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&gid=22226&Itemid
77. Drugs for Neglected Diseases initiative (DNDi). New VL treatments – Asia – DNDi [Internet]. 2015 [cited 2016 May 19]. Available from: http://www.dndi.org/diseases-projects/portfolio/new-vl-treatments-asia/
79. Olliaro PL. Drug combinations for visceral leishmaniasis. Curr Opin Infect Dis 2010; 23(6):595–602. https://doi.org/10.1097/QCO.0b013e32833fca9d
81. Meheus F, Balasegaram M, Olliaro P, Sundar S, Rijal S, Faiz MA, et al. Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Negl Trop Dis 2010; 4(9):e818. https://doi.org/10.1371/journal.pntd.0000818
83. Omollo R, Alexander N, Edwards T, Khalil EAG, Younis BM, Abuzaid AA, et al. Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial. Trials 2011; 12:166. https://doi.org/10.1186/1745-6215-12-166
85. Directorate of National Vector Borne Disease Control, Programme (NVBDCP), Directorate General of Health Services Minister of Health & Family Welfare 22 Sham Nath Marg D-54. National Roadmap for Kala-Azar Elimination Agosto 2014 [Internet]. Delhi; 2014. Available from: http://nvbdcp.gov.in/Doc/Road-map-KA_2014.pdf
87. Freitas-Junior LH, Chatelain E, Kim HA, Siqueira-Neto JL. Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? Int J Parasitol Drugs drug Resist 2012; 2:11–9. https://doi.org/10.1016/j.ijpddr.2012.01.003
89. Singh N, Kumar M, Singh RK. Leishmaniasis: current status of available drugs and new potential drug targets. Asian Pac J Trop Med 2012; 5(6):485–97. https://doi.org/10.1016/S1995-7645(12)60084-4
91. Don R, Ioset J-R. Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections. Parasitology 2014; 141(1):140–6. https://doi.org/10.1017/S003118201300142X
93. Siqueira-Neto JL, Song O-R, Oh H, Sohn J-H, Yang G, Nam J, et al. Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds. PLoS Negl Trop Dis 2010; 4(5):e675. https://doi.org/10.1371/journal.pntd.0000675
95. Loiseau PM, Cojean S, Schrével J. Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance. Parasite 2011; 18(2):115–9. https://doi.org/10.1051/parasite/2011182115
97. Sen R, Chatterjee M. Plant derived therapeutics for the treatment of Leishmaniasis. Phytomedicine 2011; 18(12):1056–69. https://doi.org/10.1016/j.phymed.2011.03.004